Kaplan-Meier curves for secondary end points for patients with r/r FL who received tisagenlecleucel infusion. (A) PFS, (B) DOR, (C) OS, and (D) TTNT in the EAS (n = 94). PFS, DOR, and OS by best overall response (BOR) curves are per IRC assessment. TTNT curve is per local assessment. Censoring times are shown as squares. EAS, efficacy analysis set; IRC, independent review committee; NE, not estimable.